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Background: Specific cross-reacting autoimmunity against recoverin or collapsin response mediator protein
(CRMP)-5 is known to cause cancer-associated retinopathy or paraneoplastic optic neuropathy, respectively.
We report a rare case with small cell lung carcinoma developing bilateral neuroretinitis and unilateral focal outer
retinitis positive for these antibodies.
Case presentation: A 67-year-old man developed bilateral neuroretinitis and foveal exudation in the right eye.
Optical coherence tomography showed a dome-shaped hyperreflective lesion extending from inner nuclear layer to
the photoreceptor layer at the fovea in the right eye. Single-flash electroretinography showed normal a-waves in
both eyes and slightly reduced b-wave in the left eye. Results of serological screening tests for infection were within
normal limits. The patient’s optic disc swelling and macular exudation rapidly improved after oral administration of
prednisolone. Systemic screening detected lung small cell carcinoma and systemic chemotherapy was initiated.
Immunoblot analyses using the patient’s serum detected autoantibodies against recoverin, CRMP-5, and α-enolase,
but not carbonic anhydrase II. Neuroretinitis once resolved after almost remission of carcinoma on imaging but it
recurred following the recurrence of carcinoma.
Conclusions: The development of neuroretinitis in this cancer patient with anti-retinal and anti-optic nerve
antibodies depended largely on the cancer activity, suggesting the possible involvement of paraneoplastic
mechanisms. Patients with paraneoplastic optic neuropathy and retinopathy are likely to develop autoimmune
responses against several antigens, thus leading to various ophthalmic involvements.
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Outer retinitisBackground
Paraneoplastic retinopathy including cancer-associated
retinopathy (CAR) and paraneoplastic optic neuropathy
(PON) are autoimmune diseases in which the host re-
sponse to tumor antigens triggers cross-reactions to an
overlapping epitope in the retina and/or the optic nerve
[1]. A 23-kDa recoverin protein, localized in photorecep-
tors, is one of the major antigens linked with CAR [2,3].* Correspondence: wsaito@med.hokudai.ac.jp
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reproduction in any medium, provided the orPatients with CAR basically exhibit no abnormal retinal
appearances in the initial stage and may later develop
diffuse pigment epithelial degeneration similar to retin-
itis pigmentosa together with photoreceptor degener-
ation [1]. Multiple ancillary tests including immunoblot
analyses using patients’ sera, systemic screening, electro-
retinography, and perimetry are needed for a diagnosis
of CAR. As for autoantigens causing PON, collapsin re-
sponse mediator protein (CRMP)-5 has been most fre-
quently reported [4-7]. Patients with anti-CRMP-5
antibody-positive PON generally develop funduscopic
features of neuroretinitis [5]. On the other hand, somed. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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as retinal vasculitis [1,8]. In this report, we describe a
rare case with small cell lung carcinoma positive for
anti-recoverin antibody and anti-CRMP-5 antibody pre-
senting bilateral neuroretinitis and focal outer retinitis.
Case presentation
A 67-year-old man suffered from progressive central vision
loss OD for one month with no photopsia, night blindness,
or extraocular symptoms including headache. The patient
had medical history of pulmonary emphysema and non-
contributory family history. Best-corrected visual acuity
(BCVA) was 0.08 OD and 1.2 OS. Relative afferent pupillaryFigure 1 Photographs at the first visit (a-f) and two weeks after (g, h
carcinoma. Fundus photograph showing optic disc swelling surrounded b
eyes, and a subretinal opaque exudation at the fovea in the right eye (a, ri
hyperfluorecence corresponding to the foveal lesion and the optic disc 140
marked leakage from the optic disc, and retinal vasculitis (arrows) on the la
(OCT) showing a dome-shaped hyperreflective lesion at the fovea and SRD
OCT showing intact the photoreceptor inner segment/outer segment junc
macula in the left eye (g, arrow). Single-flash electroretinography demonstr
left eye (h).defect (RAPD) was negative. Slit-lamp biomicroscopy
showed moderate cells in the anterior vitreous OU. Fun-
duscopy revealed swollen optic disc surrounded by serous
retinal detachment (SRD), dilated tortuous veins OU, and
subretinal opaque exudation at the fovea OD (Figure 1a,b).
Fluorescein angiography showed initial hyperfluorescence
with late leakages from the optic disc and retinal venous
wall staining OU, and hyperfluorescence from the initial
phase at the fovea OD (Figure 1c,d). Indocyanine green
angiography revealed normal appearances OU except for
slight hypofluorescence on the late phase corresponding to
the foveal lesion OD. Optical coherence tomography
(OCT) showed SRD adjacent to the optic disc OU and a) in a 67-year-old neuroretinitis patient with small cell lung
y serous retinal detachment (SRD) and dilated tortuous veins in both
ght eye, b, left eye). Fluorescein angiography of the right eye showing
second after the dye injection (c), and the foveal tissue staining,
te phase (d). Horizontal section of optical coherence tomography
(e, arrow) adjacent to the optic disc in the right eye (e). Horizontal
tion (IS/OS) line at the macula in the left eye (f). SRD extended to the
ated normal a-wave in both eyes and slightly reduced b-wave in the
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inner nuclear layer to the photoreceptor layer correspond-
ing to the foveal exudation OD (Figure 1e). In the left eye,
the photoreceptor inner segment/outer segment junction
(IS/OS) line was intact at the macula (Figure 1f). Goldmann
perimetry showed blind spot enlargement of 20 × 20 OU
and central scotoma of 10 × 10 OD. P100 latency of visual
evoked potential (VEP) responses showed no prolongation
OU (R: 111.3 ms L: 112.3 ms). Brain and orbital magnetic
resonance imaging (MRI) revealed no abnormalities.
Two weeks after the first visit, BCVA decreased to 0.02
OD and 0.3 OS, with aggravation of the optic disc swelling
OU and development of SRD at the macula OS (Figure 1g).
Single bright-flash electroretinography (ERG) showed nor-
mal a-wave OU and slightly reduced b-wave OS (Figure 1h).
Results of serological screening tests for infection, in-
cluding syphilis and anti-Bartonella henselae antibody,
as well as autoantibodies for autoimmune diseases were
within normal limits.
Oral administration of prednisolone (PSL) at the dose
of 30 mg a day was initiated and was continued during 5
months, based on a diagnosis of bilateral neuroretinitis.
Swollen optic disc and SRD quickly reduced after treat-
ment. Systemic screening detected lung small cell carcin-
oma of extensive-stage disease and systemic chemotherapy
was initiated. Five months after treatment, optic disc
swelling disappeared OU with foveal scar formation OD
(Figure 2a,b). On OCT, SRD and a foveal hyperreflective
lesion disappeared with intact IS/OS line OS (Figure 2c,d).
BCVA increased to 0.08 OD and 1.2 OS. Immunoblot ana-
lyses using the patient’s serum detected autoantibodies
against recoverin, CRMP-5, and α-enolase (Figure 3), but
not carbonic anhydrase II (data not shown). Chemother-
apy was discontinued because imaging showed near-
complete disappearance of lung carcinoma. One monthFigure 2 Photographs 5 months after systemic corticosteroid treatme
swelling and SRD in both eyes and foveal scar formation in the right eye (a
SRD in both eyes and a foveal hyperreflective lesion in the right eye, withafter withdrawal of chemotherapy, lung carcinoma re-
curred and systemic chemotherapy was resumed. Two
months after recurrence of carcinoma, optic disc swelling
also recurred and oral PSL was restarted. At the last visit,
3 months after the initiation of retreatment with PSL,
optic disc swelling disappeared again OU. In OCT, the
IS/OS line remained intact OU except for the fovea OD.
The results of single bright-flash ERG were normal OU.Immunoblot analyses
Plasmid construction and protein expression
The human Recoverin cDNA (GenBank No. NM_002903)
was subcloned into pGEX4T-2 vector (GE Healthcare,
Piscataway, NJ), and glutathione S-transferase (GST) fu-
sion recoverin protein was expressed in Escherichia (E.)
coli strain Rosetta-gami 2 (DE3) (Novagen, Madison, WI).
GST fusion proteins were purified through binding to
Glutathione-Sepharose (GE Healthcare).Immunoblot analyses for recoverin, CRMP-5, α-enolase, and
carbonic anhydrase II
Recombinant human CRMP-5, α-enolase, and carbonic
anhydrase II proteins were purchased from Abnova
(Taipei, Taiwan), Biovision (Milpitas, CA), and ATGen
(Gyeonggi-do, South Korea), respectively. Proteins were
solubilized in 2 × SDS (sodium dodecyl sulfate) sample
buffer by heating to 100°C for 5 minutes and separated
by 10% SDS-PAGE. Then, proteins were transferred to
PVDF (polyvinylidene fluoride) membrane by electro-
blotting, and immunoblot analyses were performed
using patient’s and control’s serum (1/2000 dilution),
anti-recoverin antibody (1/20000, Millipore, Billerica,
MA), anti-CRMP-5 antibody (1/2000, GeneTex, Irvine, CA),
anti-α-enolase antibody (1/2000, Santa Cruz Biotechnology,nt. Fundus photographs showing the disappearance of the optic disc
, right eye, b, left eye). Horizontal OCT showing the disappearance of
intact IS/OS line in the left eye (c, right eye, d, left eye).
Figure 3 Immunoblotting results in our patient. Immunoblot analyses revealed predicted protein bands of approximately 49 kDa
[recombinant human recoverin (23 kDa)-fusion GST (glutathione S-transferase, 26 kDa) protein] (a), 88 kDa [recombinant human CRMP-5
(62 kDa)-fusion GST protein] (b), and 46 kDa [recombinant human α-enolase (46 kDa)] (c) in the patient’s and control’s sera.
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2000, Abcam, Cambridge, MA), as previously described [9].
Discussion
Bilateral neuroretinitis with unilateral focal outer retin-
itis developed in a cancer patient positive for autoanti-
bodies against recoverin, CRMP-5, and α-enolase. The
ocular manifestations depended largely on comorbid
cancer activity, suggesting the possible involvement of
paraneoplastic mechanisms in the ocular disorder.
Neuroretinitis is an inflammatory disorder character-
ized by optic disc edema and the surrounding exudation
despite with or without RAPD [10]. In the differential
diagnosis, papilledema and optic disc tumors were elimi-
nated owing to the lack of abnormal brain or orbital
MRI findings. Hypertensive retinopathy was also denied
based on the absence of systemic hypertension. Anterior
ischemic optic neuropathy was differentiated based on
negative RAPD and the presence of anterior vitreous
cells and retinal vasculitis. Vogt-Koyanagi-Harada dis-
ease was excluded because the patient had no extraocu-
lar symptoms of the disease and indocyanine green
angiography showed no choroidal inflammation, such as
multiple hypofluorescent spots that appear during the
middle phase. Infectious neuroretinitis was denied be-
cause of the negative serological screening results in-
cluding Bartonella henselae.
The pathogenesis of neuroretinitis is generally regarded
as vasculitis at the optic disc [10]. In this patient, a pos-
sible cause of optic disc swelling was thought to be vascu-
litis rather than neuritis because of several findings such
as negative RAPD, normal P100 latency in VEP, and blind
spot enlargement in perimetry. Anti-CRMP-5 antibody-
positive PON presents optic neuritis or neuroretinitis
characterized by optic disc swelling, the leakages of theoptic disc and retinal vessels on FA, and anterior vitreous
cells [4,5]. Since the CRMP-5 protein localizes at oligo-
dendrocytes within the myelin sheath of the optic nerve
[6], bilateral neuroretinitis in this patient is thought to re-
sult from inflammation at the vicinity of the optic nerve
caused by CRMP-5-related autoimmunity.
The present case also involved unilateral focal outer
retinal inflammation with suspected fibrin formation at
the fovea, which quickly responded to systemic cortico-
steroid therapy and completely resolved with the
remaining loss of the IS/OS line. To our knowledge, no
previous reports have shown such findings in patients
with anti-CRMP-5 antibody-positive PON [4-7]. Reason-
ably, autoantibodies other than anti-CRMP-5 antibody
were likely to play a role in the pathogenesis of the outer
retinal inflammation.
Our case presented with not only the anti-CRMP-5 anti-
body but also the antibody for recoverin, a major cause of
CAR. To our knowledge, only one case with both anti-
bodies has been reported [11]. However, the ophthalmic
findings in this case differed from those presented here;
the former case had no initial retinal or optic disc abnor-
malities and later developed optic disc pallor [11]. Basic-
ally, anti-recoverin antibody-positive CAR patients have
diffuse photoreceptor damage in ERG and OCT [12]. In
the present case, however, photoreceptors were preserved
except for the fovea OD from these OCT findings and
preserved a-wave amplitude on ERG, suggesting an under-
lying cause distinctly different from typical cases with
anti-recoverin antibody-positive CAR.
Recoverin is reported to be highly uveitogenic and anti-
genic in rodents and cause experimental autoimmune
uveitis (EAU) together with recoverin-specific autoanti-
body induction and severe photoreceptor degeneration
[13,14]. The histopathological analysis in a recoverin-
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the level of the photoreceptor to the outer plexiform
layers in the early stage, which were similar to the OCT
images of focal outer retinal inflammation in this case
(Figure 1e). Moreover, all the aspects of recoverin-induced
EAU and photoreceptor degeneration could be repro-
duced in naïve animals by the adoptive transfer of stimu-
lated lymphocytes from animals previously immunized
with recoverin, suggesting a possible association of cellular
immunity with the recoverin-induced ocular disorder [13].
Regarding the pathogenesis by which anti-recoverin
antibody causes CAR, it has been demonstrated that the
antibody triggers photoreceptor cell death through apop-
tosis [2,15]. However, the association of T cell-mediated
autoimmunity in CAR remains elusive. A case with CAR-
like disease with no malignancy (benign Warthin tumor)
was reported to develop bilateral vitritis, optic disc pallor
and retinal vascular sheathing in addition to the typical
CAR-related sign of non-recordable ERG [16]. Import-
antly, lymphocyte proliferative responses demonstrated a
strong cellular reaction to recoverin, suggesting the valid-
ity of recoverin-specific autoimmunity in the pathogenesis
of this CAR-like disease, which was then termed “reco-
verin-associated retinopathy (RAR)” [16]. We have re-
ported the case of a benign tumor with anti-recoverin
antibody-positive retinopathy manifesting typical CAR
(i.e., photoreceptor degeneration) and retinal vasculitis
with macular edema. Surprisingly, colonic adenoma excised
from the patient was potently immunopositive for reco-
verin, leading us to advocate “benign tumor-associated ret-
inopathy (BAR)” [17].
Thus, the recoverin-mediated autoimmune retinopa-
thies (CAR, RAR and BAR) [8,16,17] and ophthalmic
findings in the present case potentially harbor inflamma-
tory features; however, in this cancer patient, it remains
unclear why photoreceptors were mostly intact despite
the induction of antirecoverin antibody. Future research
is needed to elucidate the molecular and cellular mecha-
nisms underlying recoverin-associated pathogenesis of
vascular inflammation and neurodegeneration.
α-enolase is another antigen that causes CAR or PON,
as this protein localizes at both the retina and the optic
nerve [6]. Anti-α-enolase antibody-positive CAR patients
have relatively mild clinical course that varied from sta-
bility to years to slow progression [18], suggesting its
weaker pathogenicity than anti-recoverin antibody.
Therefore, this antibody might contribute less than the
other antibody present to the development of this pa-
tient’s ophthalmic findings.
Conclusion
In conclusion, we encountered a case with small cell
lung carcinoma that was thought to be paraneoplastic
neuroretinitis and focal outer retinitis. Patients withparaneoplastic optic neuropathy and retinopathy are
likely to develop autoimmune responses against several
antigens, as shown in the present case, thus leading to
various ophthalmic involvements.
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